Paraproteinemias  >>  pegylated liposomal doxorubicin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00561743: A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Completed
2
50
US
Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone
Janssen-Ortho Inc., Canada
Multiple Myeloma
05/07
05/07
NCT00706953: A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Withdrawn
2
0
US
bortezomib; pegylated liposomal doxorubicin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Centocor Ortho Biotech Services, L.L.C.
Multiple Myeloma
06/10
06/10
NCT00148317: Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Completed
2
38
US
Bortezomib, velcade, dexamethasone, decadron, liposomal doxorubicin, cyclophoshamide, cytoxan, filgrastim, neupogen
Weill Medical College of Cornell University, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
02/11
11/12
NCT00366106: Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma

Terminated
2
32
US
bortezomib, Velcade, dexamethasone, Decadron, doxorubicin HCl liposome, Doxil
Accelerated Community Oncology Research Network, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
03/11
03/11
NCT01160484: Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

Checkmark P2 data
Feb 2012 - Feb 2012: P2 data
Completed
2
40
US
DVD-R, Decadron, Velcade, Doxil, Revlimid
Oncotherapeutics, Celgene Corporation
Multiple Myeloma
12/11
09/12
NCT00617591: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Completed
2
57
US
Lenalidomide, Revlimid®, Pegylated Liposomal Doxorubicin (PLD), Doxil®, Dexamethasone, Decadron®
H. Lee Moffitt Cancer Center and Research Institute, Celgene Corporation, Ortho Biotech Clinical Affairs, L.L.C.
Multiple Myeloma
04/13
04/13
NCT01492881: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Withdrawn
2
0
US
Vorinostat, Zolina, Bortezomib, Velcade, pegylated liposomal doxorubicin, Doxil
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Multiple Myeloma
01/15
01/17
NCT00750815: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Completed
1/2
58
US
Cyclophosphamide, Cytoxan, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD), VELCADE, DOXIL®, PLD, CVDD, VDD
H. Lee Moffitt Cancer Center and Research Institute, Millennium Pharmaceuticals, Inc., Ortho Biotech, Inc.
Multiple Myeloma
12/12
05/13
NCT01177683: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Terminated
1/2
32
US
Bendamustine, Doxorubicin, Bortezomib, Filgrastim
Sherif Farag, MB, BS, Hoosier Cancer Research Network, Cephalon, Inc.
Multiple Myeloma
12/17
12/17

Download Options